ATL1102 is an antisense oligonucleotide designed to inhibit CD49d expressed on T cells implicated in the inflammatory/immune response in Duchenne. Inhibition of CD49d aims to decrease the inflammation that accompanies loss of dystrophin in Duchenne.

Status

A Phase 2A trial is complete.

Sponsor

This program is sponsored by Antisense Therapeutics.

Media Library